1.
Effects of Euglena gracilis EOD-1 Ingestion on Salivary IgA Reactivity and Health-Related Quality of Life in Humans.
Ishibashi, KI, Nishioka, M, Onaka, N, Takahashi, M, Yamanaka, D, Adachi, Y, Ohno, N
Nutrients. 2019;11(5)
-
-
-
Free full text
Plain language summary
Euglena gracilis is a single cell algae which inhabits most garden ponds. Euglena is rich in several nutrients and produces paramylon, a type of carbohydrate known as β-glucan, which has been shown in animal studies to have several health benefits. This study looked at the effects of E. gracilis on the immune system and quality of life (QOL) in humans. Seven healthy men aged 30-70 completed the study. Subjects were split into two groups and instructed to take 500mg/day of either the E. gracilis or a placebo (cornstarch) for 4 weeks. After a break, the groups were swapped, and the experiment repeated for another 4 weeks. The researchers found that ingestion of the algae increased the amount of salivary s-IgA secretion, and was able to activate the mucosal immune system in such a way that could potentially enhance the immune response against microbial infections such as Candida and Aspergillus. Ingestion of the algae also improved scores in both mental and physical health. Due to the limited number and diversity of subjects, further studies with a larger number of more diverse subjects are needed. The researchers suggest that Euglena gracilis would be a useful functional food for humans.
Abstract
Euglena gracilis EOD-1, a microalgal strain known for high yields of the β-1, 3-glucan paramylon, is suggested to function as a dietary fiber and enhance immunity. Here, we aimed to investigate the effects of E. gracilis EOD-1 biomass (EOD1BM) ingestion on immunoglobulin A (IgA) antibody titers in saliva, its reactivity, and the health-related quality of life (QOL) in humans. Reacting human immunoglobulin preparations and saliva with paramylon granules revealed the presence of anti-paramylon antibodies in the blood and saliva. We conducted a placebo-controlled, double-blind, crossover study involving 13 healthy subjects who ingested the placebo or EOD1BM for 4 weeks. Saliva was collected from each subject before and after ingestion, and IgA titers and E. gracilis EOD-1 paramylon (EOD1PM) reactivity were compared. In the EOD1BM Ingestion group, the anti-EOD1PM IgA content and titer increased after EOD1BM ingestion. No such change was observed in the Placebo group. Furthermore, the health-related QOL, especially mental health, increased in the EOD1BM Ingestion group. Thus, EOD1BM ingestion led to the production of paramylon (PM)-specific IgA antibody and increased salivary IgA antibody titers. We demonstrate that EOD1BM ingestion enhanced the immunity in the mucosal surface, evoked an antigen-specific response, and increased the health-related QOL, thereby contributing to health improvement.
2.
A Preclinical Evaluation of the Antitumor Activities of Edible and Medicinal Mushrooms: A Molecular Insight.
Joseph, TP, Chanda, W, Padhiar, AA, Batool, S, LiQun, S, Zhong, M, Huang, M
Integrative cancer therapies. 2018;17(2):200-209
-
-
-
Free full text
Plain language summary
Globally, the morbidity and mortality rate because of cancer is increasing constantly. Life scientists are focusing more aggressively on the development of novel agents exhibiting antitumor and anti-metastatic (inhibiting the spread of cancer cells to new areas of the body) potential with no or minimal side effects. The main aims of the study were to: (i) briefly portray a picture of genetic alterations associated with specific signalling pathways and their role in the initiation and progression of cancer, and (ii) emphasize the antitumor potential of mushroom origin compounds in a signalling pathway-specific manner. Through the literature-based evidence presented in this review, authors can anticipate the molecular mechanism of different mushroom originated compounds, where they exhibit anticancer potential through modulating different nodes of specific signalling pathways, and thus affecting a variety of cellular processes. Authors conclude that the review provides the possible molecular insight of the action of mushroom origin compounds which may be helpful in designing anticancer arsenals from mushroom for combating cancer.
Abstract
Cancer is the leading cause of morbidity and mortality around the globe. For certain types of cancer, chemotherapy drugs have been extensively used for treatment. However, severe side effects and the development of resistance are the drawbacks of these agents. Therefore, development of new agents with no or minimal side effects is of utmost importance. In this regard, natural compounds are well recognized as drugs in several human ailments, including cancer. One class of fungi, "mushrooms," contains numerous compounds that exhibit interesting biological activities, including antitumor activity. Many researchers, including our own group, are focusing on the anticancer potential of different mushrooms and the underlying molecular mechanism behind their action. The aim of this review is to discuss PI3K/AKT, Wnt-CTNNB1, and NF-κB signaling pathways, the occurrence of genetic alterations in them, the association of these aberrations with different human cancers and how different nodes of these pathways are targeted by various substances of mushroom origin. We have given evidence to propose the therapeutic attributes and possible mode of molecular actions of various mushroom-originated compounds. However, anticancer effects were typically demonstrated in in vitro and in vivo models and very limited number of studies have been conducted in the human population. It is our belief that this review will help the research community in designing concrete preclinical and clinical studies to test the anticancer potential of mushroom-originated compounds on different cancers harboring particular genetic alteration(s).